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Tumors in von Hippel–Lindau Syn-
drome: From Head to Toe—Com-
prehensive State-of-the-Art Review1
Von Hippel–Lindau syndrome (VHL) is an autosomal-dominant he-
reditary tumor disease that arises owing to germline mutations in the 
VHL gene, located on the short arm of chromosome 3. Patients with 
VHL may develop multiple benign and malignant tumors involving 
various organ systems, including retinal hemangioblastomas (HBs), 
central nervous system (CNS) HBs, endolymphatic sac tumors, pan-
creatic neuroendocrine tumors, pancreatic cystadenomas, pancreatic 
cysts, clear cell renal cell carcinomas, renal cysts, pheochromocyto-
mas, paragangliomas, and epididymal and broad ligament cystadeno-
mas. The VHL/hypoxia-inducible factor pathway is believed to play a 
key role in the pathogenesis of VHL-related tumors. The diagnosis of 
VHL can be made clinically when the characteristic clinical history 
and findings have manifested, such as the presence of two or more 
CNS HBs. Genetic testing for heterozygous germline VHL muta-
tion may also be used to confirm the diagnosis of VHL. Imaging 
plays an important role in the diagnosis and surveillance of patients 
with VHL. Familiarity with the clinical and imaging manifestations 
of the various VHL-related tumors is important for early detection 
and guiding appropriate management. The purpose of this article is 
to discuss the molecular cytogenetics and clinical manifestations of 
VHL, review the characteristic multimodality imaging features of the 
various VHL-related tumors affecting multiple organ systems, and 
discuss the latest advances in management of VHL, including current 
recommendations for surveillance and screening.
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After completing this journal-based SA-CME 
activity, participants will be able to:
 ■Describe the molecular cytogenetics 
and clinical manifestations of VHL.
 ■ Identify characteristic multimodality 
imaging features of tumors in VHL that 
affect multiple organ systems.
 ■Discuss the latest advances in manage-
ment of VHL and current recommenda-
tions for surveillance and screening.
See www.rsna.org/education/search/RG.
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introduction
Von Hippel–Lindau syndrome (VHL) is a hereditary tumor syn-
drome, arising owing to germline mutations in the VHL tumor sup-
pressor gene, located on the short arm of chromosome 3. VHL is an 
autosomal dominant disorder, with a prevalence of around one in 
36 000 and one in 50 000 live births (1,2). Around 80% of patients 
with VHL inherit the disorder from an affected parent, while it may 
arise de novo in 20% (3). The mean age of initial tumor diagnosis in 
VHL is 26 years (range, 1–70 years) (4). 
VHL is a highly penetrant disease, with more than 90% of patients 
developing symptoms by 65 years of age (1,4,5). Patients may de-
velop multiple benign and malignant tumors involving various organ 
systems, including retinal hemangioblastomas (HBs), central nervous 
system (CNS) HBs, endolymphatic sac tumors, pancreatic neuroen-
docrine tumors (NETs), pancreatic cystadenomas, pancreatic cysts, 
clear cell renal cell carcinomas (RCCs), renal cysts, pheochromocyto-
mas, paragangliomas, and epididymal and broad ligament cystadeno-
mas (Fig 1) (4). In this article, we review the molecular cytogenetics 
of VHL, discuss the characteristic multimodality imaging features of 
various VHL-associated tumors, and review the latest advances in the 
management of VHL, including surveillance and screening.
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Figure 1. Multiple RCCs and pancreatic NETs in a 32-year-old 
man with VHL. Coronal computed tomographic (CT) image of 
the abdomen shows multiple heterogeneous avidly enhancing 
lesions (white arrows) in the right kidney and numerous scat-
tered hypervascular masses (black arrows) in the pancreas.
esis of VHL-related tumors (8). The excessive 
uncontrolled angiogenesis contributes to the 
hypervascular nature of tumors that develop 
in this condition. Furthermore, the pathogenic 
VHL gene may also result in abnormal regula-
tion of the p53 tumor suppressor gene, nuclear 
factor-kB, retinol-binding protein 1, large 
subunit of ribonucleic acid (RNA) polymerase 
complex II, p400 chromatin-remodeling factor, 
and so on. The lack of a functional VHL gene 
can also lead to dysregulation of the extracellu-
lar matrix and microtubule cytoskeleton. All of 
the events previously mentioned may contrib-
ute to tumor formation in VHL.
vHL Diagnosis
VHL is associated with multiple tumors affecting 
various organs (Table 1). A VHL diagnosis can be 
made clinically when the characteristic clinical his-
tory and findings have manifested (8). The clinical 
diagnosis of VHL can be made in the following 
circumstances: (a) in a patient with a family his-
tory of VHL and at least one of the characteristic 
VHL-related tumors (eg, retinal HBs, CNS HBs, 
clear cell RCCs, pan creatic NETs, and endolym-
phatic sac tumors); (b) in the presence of two or 
more retinal or CNS HBs; or (c) in the presence 
of one retinal or CNS HB, plus at least one of the 
characteristic VHL-related visceral tumors, exclud-
ing renal and epididymal cysts.
Genetic testing for heterozygous germline 
VHL mutations may also confirm the diagnosis. 
Current indications for genetic testing include 
(a) patients with a suspected clinical diagnosis 
of VHL; (b) patients with close relatives in an 
established VHL family; and (c) patients with 
Molecular Cytogenetics and Tumor 
Pathogenesis in vHL 
Substantial advances have been made in the 
molecular cytogenetics of VHL, which have 
enhanced our understanding of the complex 
tumor biology of this condition. All patients with 
hereditary VHL inherit a single mutant defective 
allele from a germline VHL mutation. However, 
tumors develop in these patients only when a 
second somatic event affects the wild-type allele 
(Knudson “two-hit” hypothesis). 
Missense mutations (27%–52%) are the most 
common type of germline mutations reported 
in VHL. However, a wide spectrum of germline 
mutations have been described, including frame-
shift mutations, nonsense mutations, large or 
microdeletions, gene rearrangements, in-frame 
deletions or insertions, and splice site mutations 
(6). Somatic inactivation of the wild-type allele 
may arise owing to allelic loss, hypermethylation, 
or point mutations (7).
VHL is a tumor suppressor gene located on 
chromosome 3p25–26. The protein derived from 
the VHL gene plays an important role in the 
hydroxylation of the hypoxia-inducible factor 1 
alpha (HIF-a) under normoxic conditions. In 
VHL, the VHL gene becomes nonfunctional. 
Absence of the functional VHL gene leads to 
hyperaccumulation of HIF-a, which in turn can 
lead to excessive activation of numerous hypoxia-
inducible genes, including vascular endothelial 
growth factor (VEGF), platelet-derived growth 
factor, transforming growth factor, glucose trans-
porter 1, and phosphofructokinase-1. 
The VHL/hypoxia-inducible factor pathway 
is believed to play a key role in the pathogen-
TEACHing POinTS
 ■ Patients may develop multiple benign and malignant tumors 
involving various organ systems, including retinal HBs, CNS 
HBs, endolymphatic sac tumors, pancreatic NETs, pancreatic 
cystadenomas, pancreatic cysts, clear cell RCCs, renal cysts, 
pheochromocytomas, paragangliomas, and epididymal and 
broad ligament cystadenomas.
 ■ The VHL/hypoxia-inducible factor pathway is believed to play 
a key role in the pathogenesis of VHL-related tumors.
 ■ A CNS HB is the prototype tumor of VHL, which may occur in 
the cerebellum, brainstem, spinal cord, cauda equina, or su-
pratentorial region. Craniospinal HB is the most common VHL-
associated tumor, with a reported frequency of 60%–80%. 
 ■ When a cerebellar HB is identified, it is important to image 
the whole spinal cord, as lesions in the spinal cord frequently 
coexist with cerebellar lesions.
 ■ At CT, endolymphatic sac tumors may demonstrate a moth-
eaten appearance in the petrous temporal bone, with ero-
sive changes in the vestibular aqueduct, semicircular canals, 
and cochlea.
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for patient management, it should be noted that 
they are still evolving. As such, all patients with 
VHL should be screened for all possible VHL-
related tumors, irrespective of their genotypic 
characteristics (8,14).
Retinal Hbs
Retinal HBs, also called retinal angiomas or capil-
lary hemangiomas, may develop in 45%–60% of 
VHL cases (7,15). The mean age of onset is 25 
years (range, 1–68 years). Bilateral involvement 
may manifest in 50% of cases (16). Occasionally, 
these may be the sole manifestation of VHL. 
The majority of these lesions occur in the 
peripheral retina (85%) (16). Retinal HBs may 
result in various complications such as macular 
exudation, exudative or tractional retinal detach-
ment, vitreous hemorrhage, neovascular glau-
coma, and vision loss. Factors associated with 
poor visual outcome include young age of onset, 
the manifestation of juxtapapillary lesions, an in-
crease in both the number and extent of periph-
eral retina lesions, and the presence of missense 
or protein truncating mutations (16). Retinal 
HBs may result in blindness in 6% of cases.
The characteristic histologic findings of retinal 
HBs include fenestrated endothelial cells, peri-
cytes, and lipid-rich foamy stromal cells. Immu-
nohistochemical analysis has shown the presence 
of VEGF in the vacuolated stromal cells, which 
implies that these cells may represent the true 
neoplastic component of these lesions (17).
The diagnosis is confirmed with a comprehen-
sive ophthalmic examination. Ophthalmoscopy 
may show a vascular tumor with dilated tortuous 
feeding vessels and optic disc edema. Fluorescein 
angiography, fundus photography, and optical co-
herence tomography may also be useful to moni-
tor for new lesions and associated complications. 
The role of imaging is limited, but magnetic 
resonance (MR) imaging of the brain or orbit 
may show a tiny enhancing retinal nodule, with 
or without retinal detachment (Fig 2). Treatment 
options include observation (for small asymp-
tomatic lesions in the peripheral retina), argon 
laser photocoagulation, cryotherapy, photody-
namic therapy, proton-beam radiation therapy, 
and surgical excision (18).
CnS Hb
A CNS HB is the prototype tumor of VHL, which 
may occur in the cerebellum, brainstem, spinal 
cord, cauda equina, or supratentorial region (Figs 
3–7). Craniospinal HB is the most common 
VHL-associated tumor, with a reported frequency 
of 60%–80% (4,7,8,15). CNS HB is commonly 
multifocal, with one study reporting multiple CNS 
HBs in 79% of 167 cases of VHL (19).
moderate suspicion for VHL who do not satisfy 
all criteria for a clinical diagnosis, which would 
include simplex cases with one retinal or CNS 
HB, a pheochromocytoma, or an endolymphatic 
sac tumor; the presence of at least two of the 
following tumors: a pancreatic cystadenoma, 
pancreatic NET, or epididymal papillary cystad-
enoma; or the presence of clear cell RCC, plus 
any of the following features: age less than 50 
years, family history of clear cell RCC in a close 
relative, or bilateral/multifocal tumors (8).
Clinical Classification and  
genotype-Phenotype Correlations
VHL is classified as type 1, 2A, 2B, or 2C on the 
basis of clinical phenotypes. Such phenotypic 
classifications have been shown to correlate with 
specific genotypic expressions (9–14). Patients 
with VHL type 1 are characterized as low risk for 
pheochromocytoma (9) but have an increased 
prevalence of retinal and CNS HBs, RCCs, pan-
creatic cysts, and NETs. Truncating mutations 
and exon deletions have been associated with 
type 1. Some authorities have proposed a type 
1B, in which a patient has low risk for both pheo-
chromocytoma and RCC. These patients have 
large VHL gene deletions involving C3orf10 (9).
Patients with VHL type 2 harbor missense mu-
tations and carry a high risk for pheochromocy-
toma (9–13). VHL type 2 is further classified into 
type 2A (high risk for pheochromocytoma and 
low risk for RCC), type 2B (high risk for pheo-
chromocytoma and RCC), and type 2C (high 
risk for pheochromocytoma only). Although such 
genotype-phenotype correlations are promising 
Table 1: VHL Manifestations
Retina
Retinal HBs
CNS
Cerebellar and spinal HBs
Head and neck
Endolymphatic sac tumors
Pancreas
Pancreatic cysts
Serous cystadenomas
Pancreatic NETs
Kidney
Renal cysts
Clear cell RCCs
Adrenal gland
Pheochromocytoma
Reproductive organs
Epididymal cysts
Papillary cystadenoma of epididymis
Broad ligament cystadenoma
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Figure 2. Retinal HB in a 34-year-old woman with VHL. (a) Axial T2-weighted MR image of the orbit shows retinal 
detachment, with fluid in the subretinal space (arrow). (b) Axial contrast material–enhanced T1-weighted MR image 
shows a 7-mm enhancing lesion in the retina (arrow).
In VHL, CNS HBs most commonly occur in 
the cerebellum (44%–72%), followed by the spinal 
cord and brainstem (4,7,8,15). The mean age of 
onset is 33 years (range, 9–78 years). Patients with 
cerebellar HB may develop gait ataxia, dysmetria, 
headaches, diplopia, vertigo, and emesis (20,21). It 
should be noted that in many patients, the symp-
toms may be caused by the cyst or syrinx associ-
ated with the tumor rather than the tumor itself 
(19–21) (Fig 3). This is because tumor-related 
cysts/syrinxes grow at a much faster pace than the 
primary tumor and are typically larger than the 
tumor (19). Rarely, patients may develop sponta-
neous intracranial hemorrhage. Historically, cer-
ebellar HBs have been classified into four subtypes 
(22,23): type 1 (5%) is a simple cyst without a 
macroscopic nodule; type 2 (60%) is a cyst associ-
ated with a mural nodule (Fig 3); type 3 (26%) is 
a solid tumor (Fig 4); and type 4 (9%) is a solid 
tumor with small internal cysts (22,23).
Some authors have also hypothesized that cer-
ebellar HBs may begin as nodules, and those that 
remain solid may stay asymptomatic, while those 
that develop enlarging cysts may develop symp-
toms during the course of the disease (24). Mac-
roscopically, CNS HBs are well-circumscribed 
yellow solid masses or mural nodules associated 
with fluid-filled cysts. CNS HBs are classified 
as World Health Organization (WHO) grade 1 
tumors. Histologic analysis reveals a vascular cap-
illary network lined with hyperplastic endothelial 
cells, which are surrounded by pleomorphic 
vacuolated stromal cells with lipid-rich cyto-
plasm (Fig 5). A metastatic clear cell RCC may 
have a similar appearance, causing a diagnostic 
dilemma, but immunohistochemical analysis may 
help differentiate the two conditions (25).
Angiographic images show a highly vascular 
tumor with enlarged arteries and early drain-
ing veins. Computed tomographic (CT) images 
show a well-defined homogeneous cyst with an 
isoattenuating mural nodule on nonenhanced 
images (26). Contrast-enhanced CT images 
show an avidly enhancing mural nodule within 
the cyst (the so-called cyst with mural nodule 
appearance) (Table 2). MR imaging features 
mimic those at CT. The cystic component is T1 
hypointense and T2 hyperintense, and the mural 
nodule is T1 hypointense and T2 isointense or 
hyperintense.
After intravenous injection of gadolinium 
contrast material, the nodules show hypervascular 
enhancement while no enhancement is seen in the 
cyst wall. When a cerebellar HB is identified, it is 
important to image the whole spinal cord, as le-
sions in the spinal cord frequently coexist with cer-
ebellar lesions (4,21,27) (Fig 6). The differential 
diagnosis includes juvenile pilocytic astrocytoma, 
arachnoid cyst, metastases, and medulloblastoma.
Since many tumors show a saltatory growth 
pattern (a growth phase followed by a quiescent 
phase), close surveillance may be appropriate for 
asymptomatic lesions. Surgical resection is per-
formed for the symptomatic tumors, which are 
usually tumors with large associated cysts and/
or peritumoral edema. Radiation therapy has also 
been used, especially in patients with incomplete 
surgical resection.
Spinal HBs manifest in 13%–50% of cases of 
VHL. The mean age of onset is 33 years (range, 
11–66 years). Although any part of the spinal 
canal can be affected, spinal HBs are more com-
mon in the thoracic and cervical cord. Radicu-
lopathy- and myelopathy-associated symptoms 
predominate in spinal HB, including hyperesthe-
sia, weakness, gait ataxia, hyperreflexia, pain, in-
continence, and rarely quadriplegia (21). Patients 
with a brainstem HB may develop symptoms due 
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Figures 4, 5. (4) Cerebellar HB in a 28-year-old man with VHL. Sagittal contrast-enhanced T1-weighted MR image of the brain 
shows an avidly enhancing solid mass (arrow) in the posterior fossa. The appearance is consistent with type 3 cerebellar HB. Surgi-
cal pathologic analysis confirmed cerebellar HB. (5) Histopathologic findings of CNS HB. Photomicrograph shows proliferation of 
densely packed variably sized capillaries (*) with intervening polygonal stromal cells, some of which have foamy cytoplasm with 
fine vacuoles (arrows). (Hematoxylin-eosin [H-E] stain; original magnification, 3200.)
to lower cranial nerve compression and increased 
intracranial pressure (19–21).
A nonenhanced CT image may show an 
isoattenuating nodule in the spinal cord. Avid 
enhancement is seen in the spinal mass after 
intravenous contrast agent administration (Fig 
7). MR imaging helps confirm an intramedul-
lary tumor with an extramedullary component. 
The tumor nodule tends to be TI hypointense 
and T2 hyperintense and may show flow voids. 
Marked enhancement is seen on enhanced im-
ages. A syrinx is seen in 50%–100% of cases. 
The differential diagnosis includes metasta-
sis, ependymoma, meningioma, arteriovenous 
Figure 3.  Cerebellar HB in a 32-year-old woman with VHL. (a) Coronal MR im-
age of the brain obtained in 2003 shows a tiny solid enhancing nodule (arrow) in 
the right cerebellum. No cystic component is seen with the tumor. The tumor was 
monitored, as the patient was asymptomatic, and the lesion showed slow growth 
up til 2012. (b) Coronal MR image of the brain obtained in 2013 shows a slight 
increase in nodule size and a newly developed cystic component (arrow). The pa-
tient was still asymptomatic and was closely monitored. (c) Coronal MR image of 
the brain obtained in 2016 shows that the solid component has not changed much, 
but the cystic component (arrow) has significantly increased. (d) Axial T2-weighted 
MR image obtained in 2016 shows the large cystic lesion with mural nodule (arrow). 
Extensive peritumoral edema and mass effect from the enlarging cystic tumor are 
seen. The patient developed symptoms, and the tumor was successfully resected. 
Small solid nodules are usually asymptomatic, as in this case, while cystic lesions, 
especially those increasing in size and associated with peritumoral edema, often 
result in substantial symptoms that necessitate resection.
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Figures 6, 7. (6) Multiple cerebellar and spinal HBs in a 38-year-old man with VHL. (a) Axial MR image of the brain shows small 
enhancing nodules (arrows) in the cerebellum, consistent with cerebellar HB. Although the patient did not have symptoms, MR imag-
ing of the whole spine was performed. (b) Sagittal MR image of the cervical spine shows numerous tiny enhancing masses (arrows) 
in the spinal cord, consistent with spinal HB. (7) Spinal HB in a 27-year-old man with VHL. (a) Sagittal T1-weighted MR image of the 
lumbar spine demonstrates an isointense mass in the spinal cord (arrow). (b) Sagittal contrast-enhanced T1-weighted MR image of 
the lumbar spine demonstrates avid enhancement within the spinal cord mass (arrow).
Table 2: Imaging Features of VHL-related Benign and Malignant Tumors
Manifestations
Commonly Used 
Imaging Modalities* Imaging Features
Cerebellar HB MR imaging, CT Well-defined homogeneous cyst with avidly enhancing mural 
nodule at CT and MR imaging; one-fourth of the tumors may 
manifest as a solid enhancing nodule, without cystic component
Spinal HB MR imaging, CT Avidly enhancing spinal mass, flow voids may be seen; syrinx 
seen in 50%–100% of cases
Endolymphatic sac 
tumor
MR imaging, CT “Moth-eaten” appearance in the petrous temporal bone; central 
calcific spiculation and posterior rim calcification at CT; at 
MR imaging, these may be T1 hyperintense; intense enhance-
ment of the solid portions of the tumor on gadolinium-en-
hanced images
Pancreatic cyst MR imaging, CT Simple-appearing thin-walled cysts without any mural nodules or 
enhancement
Serous cystadenoma MR imaging, CT Multicystic lesion with “bunch-of-grapes appearance”; tends to 
have multiple (usually more than six) cysts, with each one mea-
suring <2 cm; enhancing central scar with stellate calcification 
(20%) may be seen; no communication with pancreatic duct
Pancreatic NET MR imaging, CT Lesions <3 cm tend to be solid and homogeneous; larger lesions 
are typically heterogeneous; avid early arterial enhancement at 
both CT and MR imaging; hypervascular liver metastases are 
often seen, especially in pancreatic tumors that are >3 cm
Renal cyst MR imaging, CT Simple-appearing thin-walled cysts without any mural nodules, 
nodular septa, or enhancement
Clear cell RCC MR imaging, CT Heterogeneous enhancing renal mass, typically as a hypervascular 
mass, which enhances more than the adjacent cortex; necrosis 
and calcification may be seen
Pheochromocytoma MR imaging, CT, 
MIBG 
Typically solid but can be cystic; avid arterial enhancement; 
marked T2 hyperintensity (“light bulb” sign) at MR imaging; 
avid tracer uptake on MIBG images
Papillary cystadenoma 
of epididymis
US Mixed solid-cystic lesions, usually vascular with increased Dop-
pler US flow; tend to be slow-growing lesions
*In VHL, MR imaging is usually preferred over CT for imaging tumors, as patients require long-term surveillance. 
MIBG = metaiodobenzylguanidine, US = ultrasonography.
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Figures 8, 9. (8) Histopathologic findings of endolymphatic sac tumor. Photomicrograph shows a papillary partly cystic tumor 
lined by cuboidal to low columnar cells with eosinophilic cytoplasm (black arrow). The cysts vary in size, and some contain eo-
sinophilic colloid-like material resembling thyroid follicles (yellow arrows). (H-E stain; original magnification, 3100.) (9) Endolym-
phatic sac tumor in a 34-year-old woman with VHL. Axial high-resolution CT image of the petrous temporal bone shows an infil-
trative aggressive mass (white arrow) in the retrolabyrinthine region, resulting in a moth-eaten appearance. The tumor contains 
intratumoral bone spicules (black arrow).
malformation, or arteriovenous fistula. Surgical 
resection and γ-knife radiation therapy may be 
offered as treatment options in the management 
of these tumors.
Endolymphatic Sac Tumor
Endolymphatic sac tumor develops in 10%–15% 
of VHL cases (Figs 8–10). The mean age of onset 
is 22 years (range, 12–50 years), and they may be 
bilateral in 30% of cases (28,29). These are benign 
tumors that occur in the vestibular aqueduct but 
are locally invasive and can erode into the adja-
cent structures such as the semicircular canals 
and cochlea. Clinical symptoms include hearing 
loss (84%–100%), tinnitus (73%–77%), vertigo 
(62%–68%), and facial nerve palsy (8%) (28–30). 
Hearing loss may be sudden (secondary to in-
tralabyrinthine hemorrhage) or gradual (usually 
owing to endolymphatic hydrops) (28). Histo-
pathologic analysis shows a highly vascular tumor, 
comprised of complex interdigitating papillary cys-
tic structures lined with cuboidal epithelium, infil-
trating the surrounding connective tissue and bone 
(Fig 8) (4). Hemorrhage, hemosiderin, cholesterol 
clefts, and clear vacuolated cells are seen.
At CT, endolymphatic sac tumors may 
demonstrate a moth-eaten appearance in the 
petrous temporal bone, with erosive changes in 
the vestibular aqueduct, semicircular canals, and 
cochlea (31,32) (Fig 9). Central calcific spicula-
tion and posterior rim calcification are commonly 
seen (31,32). Enhanced images show an avidly 
enhancing tumor. 
At MR imaging, these tumors may be T1 
hyperintense (secondary to hemorrhagic and 
proteinaceous contents) and T2 hyperintense 
(31,32). Intense enhancement of the solid por-
tions of the tumor is seen on gadolinium-en-
hanced images (Fig 10). Accurate early diagnosis 
of endolymphatic sac tumors followed by prompt 
surgical resection is critical, as they can help 
prevent or reduce hearing loss and other audio-
vestibular symptoms (30).
Renal Manifestations
Multicentric renal cysts and clear cell RCCs 
may manifest in more than two-thirds of VHL 
cases (15) (Figs 11–16). Even grossly normal 
renal parenchyma may demonstrate hundreds 
of microscopic renal cysts and tumors (33). The 
cystic lesions may be a combination of simple be-
nign cysts, complex atypical cysts with epithelial 
hyperplasia/cytologic atypia, or cystic RCCs (34) 
(Figs 11–13). The number and size of the cysts 
in VHL have not been shown to be associated 
with malignant potential (34). Patients may be 
asymptomatic despite the manifestation of a large 
number of cysts.
VHL is characterized by the development of 
a clear cell RCC histologic subtype (4,14,27). 
The prevalence of RCC in VHL varies from 
25% to 45%, with the frequency increasing 
with age (4,8,15). VHL-related RCCs tend to 
develop at a much younger age compared with 
that of sporadic RCCs. The mean age of on-
set for VHL-related RCCs is 39 years (range, 
13–70 years), and clear cell RCCs are frequently 
bilateral (Figs 12–14). It should be noted that 
bilateral clear cell RCCs on their own are not 
diagnostic of VHL, as other hereditary renal tu-
mor syndromes and rarely even sporadic tumors 
may manifest as bilateral multifocal tumors (8). 
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Figures 11, 12. (11) Diffuse bilateral renal cysts in a 34-year-old man with VHL. Coronal T2-weighted im-
age of the abdomen shows diffuse bilateral hyperintense cysts in both kidneys. (12) RCC and renal cyst in a 
41-year-old man with VHL. Coronal contrast-enhanced T1-weighted MR image shows bilateral cystic lesions 
with thick septa (white arrow), a solid heterogeneous enhancing left renal mass (black arrow), and a simple 
right renal cyst (arrowhead).
However, the presence of bilateral or multifocal 
clear cell RCCs or tumors in patients younger 
than 50 years of age is an indication for VHL 
genetic screening (Fig 12). 
Gross pathologic analysis of a solid RCC shows 
a well-defined encapsulated gold-yellow-tan 
variegated mass, which may demonstrate cystic 
degeneration and hemorrhage. Histopathologic 
analysis demonstrates nests of epithelial cells with 
clear cytoplasm and well-defined cell membranes, 
separated by highly vascularized stroma (Fig 15).
Ultrasonography (US) may help differentiate 
solid from cystic renal masses. Although contrast-
enhanced US is promising, its use for assessing 
complex renal lesions in VHL is not yet clear. 
Currently, renal lesions are usually further evalu-
ated at CT or MR imaging. Renal protocol CT 
with nonenhanced, corticomedullary, nephro-
graphic, and occasionally excretory phase imag-
ing is useful for characterizing renal lesions. 
At CT, solid RCCs tend to be heterogeneous 
and demonstrate early avid enhancement, followed 
by washout in the delayed phase (Fig 1). At MR 
imaging, solid RCCs tend to be T1 hypointense, 
although the presence of hemorrhage may result in 
T1 hyperintense foci. The presence of intracellular 
lipid in clear cell RCCs may rarely result in signal 
loss with out-of-phase chemical shift MR imaging 
sequences. Tumors are typically T2 hyperintense 
and demonstrate avid heterogeneous enhance-
ment (Figs 12, 13, 16). Cystic RCCs may manifest 
as cysts with enhancing solid components and/or 
thick nodular septa (Fig 12). In contrast, simple 
renal cysts are homogeneously T1 hypointense 
and T2 hyperintense and lack enhancement on 
dynamic contrast-enhanced images. 
MR imaging is increasingly used to monitor 
VHL, as it offers several advantages compared 
with CT. MR imaging is not associated with any 
radiation exposure, which makes it an attractive 
Figure 10. Endolymphatic sac 
tumor in a 44-year-old woman 
with VHL. (a) Axial T2-weighted 
MR image of the petrous temporal 
bone shows a heterogeneous hy-
perintense mass (arrow) in the left 
retrolabyrinthine region. (b) Axial 
contrast-enhanced T1-weighted 
MR image shows avid enhance-
ment in the mass (arrow).
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tool, as long-term surveillance is required for 
VHL patients. Furthermore, many patients with 
VHL may have renal impairment owing to prior 
renal surgery and therefore may not be able to 
receive intravenous contrast agents. In these cir-
cumstances, nonenhanced MR imaging provides 
a much better assessment of VHL-related tumors 
compared with that of nonenhanced CT. 
In addition, MR imaging can be useful for 
patients with an allergy to iodinated intrave-
nous contrast agents. Finally, MR imaging may 
be superior to CT for evaluating renal lesions, 
especially smaller lesions. Small renal cysts, par-
ticularly those that are less than a centimeter, are 
difficult to evaluate at CT owing to the phenom-
enon of pseudoenhancement, which makes it 
challenging to differentiate the cysts from small 
RCCs (35). This pitfall can be overcome with 
MR imaging.
Traditionally, RCCs associated with VHL were 
treated with radical nephrectomies. This approach 
Figures 13–15.  (13) Bilateral RCCs in a 32-year-old man. Axial contrast-enhanced T1-weighted MR image of the 
abdomen shows numerous bilateral heterogeneously enhancing lesions (arrows) in both kidneys. Given the presence 
of bilateral multifocal clear cell RCCs in a young patient, the appearance raised concern for VHL. The diagnosis was con-
firmed with genetic testing. (14) Bilateral RCCs in a 42-year-old man with VHL. Coronal contrast-enhanced MR image 
of the abdomen demonstrates hypervascular heterogeneous bilateral renal masses (arrows). Surgical clips are also seen 
in the left suprarenal region, consistent with a history of left adrenalectomy for pheochromocytoma. The larger 4-cm 
mass in the interpolar region of the left kidney was chosen for partial nephrectomy, while the other lesions (which were 
<3 cm) were closely monitored. (15) Photomicrograph of clear cell RCC shows nests of tumor cells with delicate vas-
cular patterns (arrows). The cells have clear cytoplasm and low-grade nuclei. (H-E stain; original magnification, 3100.)
mandated the need for renal replacement thera-
pies such as dialysis or transplantation, which are 
associated with reduced functional outcome and 
quality of life. However, studies have clearly shown 
that partial nephrectomies are associated with sig-
nificantly higher cancer-free survival rates at 5 and 
10 years compared with those of radical nephrec-
tomies, and they have now become the standard 
of care (36,37). Furthermore, the need for dialysis 
is reported to be low, even after multiple partial 
nephrectomies, implying that these nephron-
sparing surgeries offer both superior oncologic 
and functional outcomes compared with those of 
radical nephrectomies (36,37).
Several studies have evaluated the growth ki-
netics of RCC in VHL, and the results have been 
variable. Choyke et al (38) reported that VHL-
associated RCCs may grow at a rate of 0.2–2.2 
cm/year, with a mean growth rate of 1.6 cm/year. 
Another study involving 64 VHL cases with 96 
renal tumors reported a mean growth rate of 0.4 
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cm/year and a mean volume doubling time of 
26 months (39). Many health care centers use a 
tumor larger than 3 cm as the cutoff for a partial 
nephrectomy, as the metastatic potential below 
this size has been shown to be exceedingly low 
(40,41). However, it should be noted that there is 
a high risk of de novo recurrent tumors in VHL, 
and the need for repeat partial nephrectomies 
may be as high as 63%–85% (37,42). Therefore, 
some authors have proposed a 4-cm cutoff size 
for surgery, as this might help to delay the time to 
surgery and also potentially decrease the number 
of repeat surgeries, thereby reducing complica-
tion rates (43).
Image-guided ablative procedures such as 
radiofrequency ablation and cryoablation may 
play an important role in the management of 
VHL-related RCCs. Noncystic RCCs measur-
ing 2–3 cm have been successfully treated with 
ablative procedures, with studies reporting up to 
a 100% 5-year cancer-specific survival rate (44–
46) (Fig 16). However, cystic RCCs and tumors 
closely related to major abdominal structures 
are contraindications for ablative procedures 
(46). Furthermore, the recurrence rates may be 
higher after ablative procedures compared with 
those of partial nephrectomies, and therefore, 
these patients require continued close monitor-
ing (44–46).
There was a paradigm shift in the manage-
ment of metastatic RCCs after the advent of tar-
geted therapy. Numerous tyrosine kinase agents 
have been approved by the U.S. Food and Drug 
Administration for metastatic RCCs, such as 
sorafenib, sunitinib, pazopanib, and axitinib. Al-
though the number of studies that have evaluated 
these drugs in VHL-associated RCCs is small, the 
initial results have been promising, and further 
studies are currently under investigation (47,48).
Pancreatic Manifestations
Patients with VHL can develop pancreatic cysts, 
serous cystadenomas, and pancreatic NETs 
(4,14,27) (Figs 17–22). Pancreatic cysts are com-
mon in VHL and may be seen in 42% of cases 
(range, 7%–72%) (Fig 17) (49). These are typi-
cally multiple and usually asymptomatic. Inter-
estingly, pancreatic cysts may be the only mani-
festation in about 12% of patients at the time of 
initial VHL diagnosis (49). 
Serous cystadenomas occur in 11% of patients 
(range, 9%–17%) (49–51). At histopathologic 
analysis, serous cystadenomas demonstrate well-
demarcated multilocular clusters of small cysts, 
separated by thin fibrous septa. These cystic 
lesions are lined by cuboidal cells, without mucin 
or papillary structures. Both pancreatic cysts and 
serous cystadenomas tend to be asymptomatic, 
Figure 16. RCC in a 46-year-old woman with VHL who underwent right radical 
nephrectomy 10 years earlier, as well as partial nephrectomy in the left kidney 3 
years earlier. (a, b) Axial nonenhanced T1-weighted (a) and contrast-enhanced T1-
weighted (b) MR images of the left kidney show a hypervascular enhancing solid 
mass (arrow) in the left kidney. (c) Axial high b-value diffusion-weighted MR image 
shows restricted diffusion in the lesion (arrow). The patient underwent cryoablation 
of the left RCC. (d) Axial T2-weighted MR image shows a cryoprobe, causing cryo-
ablation of the left renal mass.
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but larger lesions may cause nonspecific abdomi-
nal pain, and extensive cystic lesions replacing 
most of the pancreas may result in pancreatic 
insufficiency and diabetes mellitus (52).
Imaging, especially CT and MR imaging, 
plays an important role in the evaluation of pan-
creatic lesions in VHL. At CT, pancreatic cysts 
are seen as hypoattenuating lesions with fluid 
attenuation and demonstrate no enhancement. 
Serous cystadenomas occur as lobulated multi-
locular septated cystic masses. CT images show a 
multicystic lesion with the characteristic bunch of 
grapes appearance (Fig 18). These benign cystic 
lesions have multiple cysts (usually more than 
six), and each cyst measures less than 2 cm. An 
enhancing central scar with stellate calcification 
(20% of cases) may be seen. 
MR imaging shows a T1 hypointense and T2 
hyperintense “cluster of cysts.” The central fibrotic 
scar may be hypointense on both T1- and T2-
weighted images and can demonstrate delayed 
enhancement. Serous cystadenomas do not com-
municate with the pancreatic duct, which helps 
differentiate them from intraductal papillary muci-
nous neoplasms. When multiple simple pancreatic 
cysts are closely apposed to each other, it may be 
difficult to distinguish them from serous cystad-
enomas. However, this differentiation may not 
be clinically relevant, as both are benign lesions, 
requiring no treatment unless symptomatic.
Pancreatic NETs develop in 15% of patients 
with VHL (range, 9%–17%) (49). The mean 
age of onset is 35 years, but NETs have been 
reported in patients as young as 13 years of age. 
About 53% of VHL-associated pancreatic NETs 
are multiple. Although any part of the pancreas 
may be involved, they are more common in 
the head and uncinate process of the pancreas. 
Figures 17, 18. (17) Pancreatic cysts in a 42-year-old man with VHL. 
Coronal T2-weighted MR image of the abdomen shows the entire 
pancreas replaced by innumerable pancreatic cysts (arrow). Although 
pancreatic cysts are usually asymptomatic, they may result in pan-
creatic insufficiency when they are extensive and replace the entire 
pancreas, as seen in this case. (18) Serous cystadenoma, pancreatic 
cysts, and pancreatic NET in a 39-year-old man with VHL. Axial con-
trast-enhanced CT image (a) and axial T2-weighted MR image (b) 
of the abdomen show a cluster of cysts with a central enhancing scar 
(white arrow) in the tail of the pancreas. These cysts have a charac-
teristic bunch of grapes appearance, with multiple cysts (more than 
six), with each cyst measuring less than 2 cm, consistent with serous 
cystoadenoma. There is an avidly enhancing solid mass in the head 
of the pancreas (black arrow), consistent with an NET. There are also 
large pancreatic cysts (arrowhead).
Figure 19. Histopathologic findings of a pancreatic NET. 
Photomicrograph shows a tumor, characterized by a trabecu-
lar pattern (arrow) and low-grade cytologic features. Adjacent 
normal pancreatic acini (*) can also be seen. (H-E stain; original 
magnification, 320.)
860 May-june 2018 radiographics.rsna.org
Figure 22. Pancreatic NET in a 43-year-old man. Axial gal-
lium 68 (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA)–octreotate (DOTATATE) positron 
emission tomography (PET)/CT image shows avid tracer 
uptake in the tumor (arrow) in the body of the pancreas.
Pancreatic NETs associated with VHL manifest 
at a much younger age compared with that of 
sporadic NETs, and they are more commonly 
multifocal. The vast majority of these pancreatic 
NETs are nonfunctional tumors (50,51). 
Although they tend to be asymptomatic, some 
NETs may result in abdominal pain, jaundice, 
pancreatitis, or even gastrointestinal bleeding 
(50). At gross pathologic analysis, these tumors 
are well circumscribed and are red-brown, gray, 
or yellow-tan (53,54). Solid trabecular or glandu-
lar architecture, with prominent small vasculature 
and stromal collagen bands, is commonly seen at 
histopathologic analysis (Fig 19). A characteristic 
feature of pancreatic NETs associated with VHL 
is the presence of clear cells and multivacuolated 
lipid-rich cells (53,54). At immunohistochemi-
cal analysis, these tumors are usually positive for 
synaptophysin, chromogranin A, inhibin,  neuron-
specific enolase, and S100.
Tumors may also demonstrate focal positivity 
for pancreatic polypeptide, somatostatin, insulin, 
and/or glucagon (53,54). The manifestations of 
angioinvasion, perineural invasion, and peritumoral 
fat infiltration are signs of locally aggressive tumors 
and may be associated with poor prognosis (53). 
The incidence of malignancy in VHL-associated 
pancreatic NETs varies from 8% to 13%, with tu-
mors demonstrating local invasion and regional or 
distant metastases (49,55). Pancreatic NETs associ-
ated with VHL are classified pathologically, as per 
the WHO classification, based on the tumor mitoses 
per 10 high-power fields and the Ki-67 index (53).
Pancreatic NETs are usually hypoattenuating 
or isointense on nonenhanced CT images. The 
Figures 20, 21. (20) Pancreatic NET and pancreatic cysts 
in a 36-year-old man with VHL. Axial contrast-enhanced 
MR image of the abdomen shows a markedly hypervascu-
lar heterogeneous mass (black arrow) in the head of the 
pancreas, consistent with an NET. Numerous scattered 
nonenhancing cysts are also seen in the pancreas (white 
arrows). (21) Pancreatic NET in a 42-year-old woman with 
VHL. (a) Axial T2-weighted MR image of the abdomen 
shows a heterogeneous hyperintense tumor (arrow) in the 
head of the pancreas. (b) Axial arterial phase gadolinium-
enhanced T1-weighted MR image shows avid enhance-
ment within the tumor (arrow).
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lesions demonstrate intense early arterial en-
hancement (Fig 20). Typically, small lesions less 
than 3 cm are solid and homogeneous. Tumors 
greater than 3 cm may be heterogeneous. It is 
important that a proper pancreatic CT protocol 
is used for evaluating these tumors, as a poor CT 
technique may lead to missed diagnosis. 
At MR imaging, pancreatic NETs are T1 
hypointense and T2 hyperintense (Fig 21). The 
enhancement pattern mimics that which is seen 
at CT (avid arterial enhancement with washout 
on delayed phase images). In most patients with 
VHL, the diagnosis of pancreatic NETs is often 
made with imaging alone. However, when there is 
a diagnostic dilemma, endoscopic US and biopsy 
may be useful for confirming the diagnosis. He-
patic metastases may be seen in pancreatic NETs, 
especially in pancreatic tumors less than 3 cm. 
The liver metastases also tend to be hypervascular, 
similar to the primary tumor. Upper abdominal 
nodal metastases may also be seen. Distant metas-
tases may also develop at other sites.
Fluorine 18 (18F) fluorodeoxyglucose (FDG) 
PET/CT has been reported to be useful in the 
management of pancreatic NETs (56–58). Al-
though CT and MR imaging may allow identifica-
tion of more NETs compared with those identified 
at 18F-FDG PET/CT, the latter may demonstrate 
extra lesions that can be occult at CT or MR 
imaging, implying that combined multimodality 
imaging using anatomic and functional imaging 
may be helpful in these patients (58). 
Furthermore, 18F-FDG PET/CT may be 
helpful for prognostication. Pancreatic NETs 
with high total lesion glycolysis at PET/CT are 
reported to be high-grade tumors, with higher 
malignant/metastatic potential compared with 
those with low total lesion glycolysis (56). Recent 
studies evaluating the clinical use of 68Ga-DOTA-
TATE PET/CT and 68Ga-DOTA-NaI3-octreotide 
PET/CT in pancreatic NETs have shown prom-
ising early results (59,60) (Fig 22).
Considering that less than 20% of pancreatic 
NETs associated with VHL are malignant, a con-
servative approach with a “watch-and-wait” strategy 
is an important part of the management of these tu-
mors. Studies have shown that about 40% of NETs 
in VHL may be stable or even decrease in size. 
Surgical resection may be appropriate for pancre-
atic NETs in VHL when the tumor size is greater 
than 3 cm (or >2 cm for lesions in the head of the 
pancreas), the tumor doubling time is less than 500 
days, there is a mutation in exon 3, or there is suspi-
cion of regional nodal metastases (51,61). 
Smaller tumors that are stable or display slow 
growth may be closely monitored with annual 
CT or MR imaging. Intraoperative US may help 
identify lesions that may be occult at CT; it can 
also demonstrate the relationship of the tumor to 
the pancreatic duct, an important feature that can 
guide the surgical approach (49). Closer follow-up 
imaging is warranted after surgical resection, espe-
cially for higher-grade tumors. CT and MR imag-
ing may be performed every 3–6 months for the 
1st year after resection and every 6 months for the 
2nd year, with annual follow-up thereafter (51).
Pheochromocytoma
Adrenal pheochromocytomas may develop in 
25%–30% of VHL cases (62,63). The mean age 
of onset is 27 years (range, 5–58 years). VHL-
associated pheochromocytomas manifest more 
commonly in boys (63), and 20%–50% may be 
bilateral (62,63) (Fig 23). The risk of developing 
a second tumor increases with age, with stud-
ies reporting a 50% risk of a second tumor at 30 
years after the initial diagnosis (63); 1%–5% of 
these tumors are malignant (63). 
Extra-adrenal pheochromocytomas/paragangli-
omas may be seen in 15% of VHL cases at various 
sites along the sympathetic chain in the abdomen, 
thorax, or head and neck. Patients may be asymp-
tomatic or experience classic symptoms such as 
paroxysmal or refractory hypertension, palpita-
tions, headaches, sweating, and hypertensive crises 
(62). A diagnosis of a pheochromocytoma is usu-
ally confirmed on the basis of biochemical abnor-
malities, including elevated plasma metanephrine 
and 24-hour urinary catecholamine levels (64).
At gross pathologic analysis, pheochromocy-
tomas manifest as lobulated yellow-red-brown 
tumors with a thick vascular tumor capsule. 
Histopathologic analysis shows a characteristic 
nesting microscopic pattern, including well-de-
fined small round tumor cells with eosinophilic 
and clear cytoplasm, separated by vascular hya-
linized stroma (Fig 24). Cystic degeneration, 
Figure  23.  Bilateral pheochromocytomas in a 22-year-old 
man with VHL. Coronal contrast-enhanced CT image of the ab-
domen shows heterogeneous avidly enhancing bilateral adrenal 
masses (arrows). Biochemical tests revealed elevated levels of 
plasma metanephrines, consistent with pheochromocytoma.
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Figure 26. Pheochromocytoma in an 18-year-old 
woman with VHL. Coronal 123I MIBG image shows avid 
uptake of MIBG in a left adrenal mass (arrow), consistent 
with pheochromocytoma.
necrosis, calcification, lipid accumulation, and 
fibrosis may be seen.
At CT, most tumors are solid heteroge-
neous lesions, but lesions may also be cystic. 
Pheochromocytomas typically show avid 
arterial enhancement (Fig 23) (65). However, 
even adenomas and hypervascular adrenal 
metastases may show similar enhancement 
characteristics (66). Absolute and relative per-
centage CT washout values of pheochromo-
cytomas and adrenal adenomas may overlap 
(66,67). Therefore, CT enhancement charac-
teristics may not necessarily help diagnose a 
pheochromocytoma (64). 
High T2-weighted signal intensity (similar to 
cerebrospinal fluid signal intensity) within the 
adrenal mass is a useful imaging feature for diag-
nosing pheochromocytoma (Fig 25) (66). Schieda 
et al (66) reported that a quantitative adrenal-to-
muscle signal intensity ratio of 3.95 or greater on 
T2-weighted images was 88% specific and 81% 
sensitive for pheochromocytomas.
Radionuclide imaging, such as iodine 131 
(131I) or 123I metaiodobenzylguanidine (MIBG) 
scintigraphy, may also be useful in imaging pheo-
chromocytoma for tumor localization and detect-
ing occult metastatic disease (Fig 26). However, 
while MIBG has a high specificity for pheochro-
mocytoma, it has a relatively low sensitivity, and 
therefore a negative image does not exclude the 
diagnosis of pheochromocytoma (64). Recent 
studies indicate that PET/CT, especially 68Ga-
DOTATATE PET/CT, may be more sensitive 
than 131I-MIBG scintigraphy for localizing meta-
static pheochromocytoma (68,69).
Minimally invasive, adrenal cortical–spar-
ing surgical resection is currently preferred for 
managing these tumors (70). Given the high risk 
of recurrence and developing second de novo 
tumors (20%–50%), surveillance with imaging 
and biochemical tests is important (63,71).
Manifestations in the 
 Reproductive Organs
Papillary cystadenomas are the most common 
VHL-related tumors developing in the repro-
ductive organs, occurring predominantly in the 
epididymis in men but may rarely develop in the 
broad ligament and mesosalpinx in women.
Epididymal papillary cystadenomas develop 
in 25%–60% of patients with VHL (Fig 27) 
(8,72,73), usually seen in young men, 20–40 
years of age. Bilateral epididymal papillary 
cystadenomas should raise strong suspicion for 
VHL, as 60% of bilateral tumors occur in VHL 
(72). Epididymal papillary cystadenomas arise 
from the efferent ductules of the epididymis 
(72). They are small tumors ranging from 1 to 
4 cm. These are usually solid tumors with cystic 
spaces filled with colloid material but may be 
predominantly cystic, with small papillae that 
are lined by glycogen-rich clear cells (72).
Figure 24. Histopathologic findings of a pheochromocy-
toma. Photomicrograph shows tumor cells arranged in small 
nests with a rich vascular network. Occasional cells with 
marked pleomorphism (arrows) are also seen. Normal adre-
nal cortical tissue is visualized at the periphery (*). (H-E stain; 
original magnification, 340.)
Figure 25. Pheochromocytoma in a 34-year-
old woman with VHL. Coronal T2-weighted 
MR image of the abdomen shows heteroge-
neous high signal intensity in a right adrenal 
mass (arrow). Since the patient was symptom-
atic, the tumor was resected. Surgical patho-
logic analysis confirmed pheochromocytoma.
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Figure 27. Epididymal papillary cystadenoma in a 31-year-old man with VHL. (a) Gray-scale US image of the left epididymis 
shows a mixed solid cystic mass in the head of the left epididymis. (b) Color Doppler US image shows marked vascularity with 
increased Doppler flow seen within the left epididymal mass. The patient was asymptomatic. The lesion was monitored with 
US follow-ups and demonstrated minimal growth.
Patients are usually asymptomatic but may 
present with incidentally identified scrotal 
masses. US appearances mimic the pathologic 
findings and range from cystic masses contain-
ing solid components to predominantly solid 
masses in the epididymis (27,73). These are 
usually vascular tumors demonstrating increased 
Doppler flow (Fig 27). Dilated efferent testicu-
lar ductules may manifest. 
Some authors have proposed the follow ing 
US criteria for diagnosing epididymal cyst-
adenomas in VHL: (a) a predominantly solid 
epididymal mass larger than 14 3 10 mm; (b) 
occurring in a patient with known VHL; and (c) 
a lesion that shows slow growth (73,74). These 
are benign tumors and are typically managed 
conservatively.
Rarely, papillary cystadenomas may manifest 
in the broad ligament in women (4,7,16,24). 
The histologic appearance of these tumors re-
sembles that of the epididymal papillary cystad-
enomas. Being benign lesions, these are usually 
managed conservatively, but surgical resection 
may be considered if symptomatic (4,7,16).
vHL Surveillance
Surveillance forms an extremely important 
component in the management of VHL and 
has been shown to increase the life expectancy 
(5). Various national guidelines exist for VHL 
surveillance, including those proposed by the 
VHL Alliance, the Dutch VHL guidelines, and 
the Danish VHL Coordination Group guidelines 
(75–77). VHL Alliance surveillance guidelines, 
which are commonly followed in the United 
States, suggest that surveillance should start at 
birth and continue lifelong (Table 3). Special 
precautions may be required during pregnancy.
Conclusion
VHL is a familial cancer syndrome caused by 
a mutation in the VHL tumor suppressor gene, 
mapped on human chromosome 3p25. Patients 
with VHL are at risk for developing numerous 
benign and malignant tumors that affect mul-
tiple organs. While some of the VHL-related 
manifestations such as renal and pancreatic 
cysts are frequently asymptomatic, other mani-
festations such as retinal and CNS HBs, RCCs, 
pheochromocytomas, and pancreatic NETs may 
be associated with significant morbidity and 
mortality. Early detection plays a key role in the 
optimal management of this condition. Radiolo-
gists should be aware of the imaging features 
of the various tumors that can occur in VHL. 
Familiarity with the current recommendations 
for VHL surveillance is also important, as these 
patients require lifelong follow-up.
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DW imaging in the chest are welcomed and do 
extend beyond what is reviewed in our article. In 
our practice, we do not routinely perform quan-
titative measurements of ADC for most thoracic 
lesions. The main purposes of DW imaging for 
our basic thoracic MR imaging protocols are to 
provide a heavily T2-weighted sequence at low 
b values as well as a means of qualitative assess-
ment of diffusion restriction using higher b values 
and the ADC map. As understanding of the 
implications of DW imaging of the chest evolves, 
quantitative analysis of DW imaging may take on 
a greater role, but it is not essential or warranted 
at present for interpretation of most thoracic MR 
imaging examinations.
Regarding the second comment by Dr Priola 
and colleagues, pertaining to our use of thoracic 
MR imaging to determine whether a suspected 
lesion has properties that make it certainly or near 
certainly benign, this is our most common indica-
tion for thoracic MR imaging. As stated in our 
article, we did not intend to provide a comprehen-
sive list of all potential indications for MR imag-
ing of the chest, and we did not imply that the 
evaluation of whether a lesion is certainly or near 
certainly benign is the only indication for thoracic 
MR imaging. The indications listed by Dr Priola et 
al in their letter are newer niche first-line indica-
tions that are promising. We sincerely hope that 
these and other indications for thoracic MR imag-
ing continue to grow and contribute to the expan-
sion of thoracic MR imaging in clinical practice. 
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Figure 23 legend: The legend should read as follows: “Bilateral pheochromocytomas in a 22-year-old man with 
VHL. Coronal contrast-enhanced CT image of the abdomen shows heterogeneous avidly enhancing bilateral adre-
nal [not renal] masses (arrows). Biochemical tests revealed elevated levels of plasma metanephrines, consistent with 
pheochromocytoma.”
